Edition:
India

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

137.09USD
20 Apr 2018
Change (% chg)

$-1.47 (-1.06%)
Prev Close
$138.56
Open
$138.79
Day's High
$139.36
Day's Low
$136.46
Volume
478,078
Avg. Vol
334,965
52-wk High
$143.22
52-wk Low
$96.70

Chart for

About

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan... (more)

Overall

Beta: 0.49
Market Cap(Mil.): $23,535.67
Shares Outstanding(Mil.): 211.16
Dividend: --
Yield (%): --

Financials

BRIEF-Boston Scientific Prevails In European Patent Dispute With Edwards Lifesciences

* BOSTON SCIENTIFIC PREVAILS IN EUROPEAN PATENT DISPUTE WITH EDWARDS LIFESCIENCES

17 Apr 2018

BRIEF-Edwards Lifesciences Corp Says CEO Michael Mussallem's FY 2017 Total Compensation Was $10.8 Mln Vs $9.7 Mln In FY 2016

* EDWARDS LIFESCIENCES CORP SAYS CEO MICHAEL MUSSALLEM'S FY 2017 TOTAL COMPENSATION WAS $10.8 MILLION VERSUS $9.7 MILLION IN FY 2016 - SEC FILING Source text: (https://bit.ly/2GUuNcF) Further company coverage:

30 Mar 2018

BRIEF-Boston Scientific says co prevails in UK Edwards Lifesciences Litigation​

* BOSTON SCIENTIFIC CORP SAYS ‍BOSTON SCIENTIFIC PREVAILS IN U.K. EDWARDS LIFESCIENCES LITIGATION​

28 Mar 2018

BRIEF-Edwards Lifesciences Prevails In U.S. Patent Office Review

* EDWARDS PREVAILS IN U.S. PATENT OFFICE REVIEW THAT FINDS BOSTON SCIENTIFIC TRANSCATHETER VALVE PATENT CLAIMS INVALID Source text for Eikon: Further company coverage:

24 Mar 2018

BRIEF-Edwards Completes Enrollment In Partner 3 Low-Risk CT Sub-Study

* EDWARDS COMPLETES ENROLLMENT IN PARTNER 3 LOW-RISK CT SUB-STUDY, UPDATES TIMELINE FOR SAPIEN 3 ULTRA SYSTEM LAUNCH IN EUROPE

22 Mar 2018

BRIEF-Edwards Lifesciences Says FDA Grants De Novo Request For Acumen Hypotension Prediction Index Software​

* EDWARDS LIFESCIENCES CORP - ‍U.S. FDA GRANTED DE NOVO REQUEST FOR EDWARDS' ACUMEN HYPOTENSION PREDICTION INDEX SOFTWARE​ Source text for Eikon: Further company coverage:

19 Mar 2018

BRIEF-Edwards Says Its Self-Expanding Transcatheter Heart Valve Receives CE Mark

* GOT CE MARK FOR SELF-EXPANDING CENTERA VALVE FOR SEVERE, SYMPTOMATIC AORTIC STENOSIS PATIENTS AT HIGH RISK OF OPEN-HEART SURGERY

15 Feb 2018

BRIEF-Edwards Lifesciences Reports Qtrly Adj EPS of $0.94

* EDWARDS LIFESCIENCES QTRLY EARNINGS PER SHARE $0.17; QTRLY ADJUSTED EARNINGS PER SHARE $0.94

02 Feb 2018

BRIEF-Edwards Lifesciences Corp Acquires Harpoon Medical

* EDWARDS LIFESCIENCES CORP - EDWARDS PAID $100 MILLION IN CASH FOR HARPOON AT CLOSING ON DEC. 1

07 Dec 2017

UPDATE 1-Edwards results fall short of Street estimates; shares tumble

Oct 24 Edwards Lifesciences Corp on Tuesday reported slightly lower-than-expected third-quarter profit and revenue and saw a dip in sales of its critically important transcatheter heart valves from the prior quarter, although they grew about 17 percent from a year earlier.

25 Oct 2017

Earnings vs. Estimates